Analyst consensus rating
MaxCyte Analyst Rating: none
Direct answer
MaxCyte's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.11.
Forecast evidence checked October 2, 2026.
Get free MaxCyte email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.10
- Average price target
- $4.11
- High price target
- $5.00
- Low price target
- $2.43
- Low target gap
- +121.9%
- Target upside
- +275.1%
- High target gap
- +356.6%
- Target range width
- 234.7%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- October 2, 2026
- Valid through
- October 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for MaxCyte?
MaxCyte has a verified none consensus. The same dataset has an average price target of $4.11.
How far are MaxCyte's low and high targets from the recorded price?
The low target implies +121.9%, while the high target implies +356.6%.
How many analysts are included in MaxCyte's consensus?
The verified consensus includes 4 analysts.
How is MaxCyte's target upside or downside calculated?
The average target of $4.11 is divided by the recorded price of $1.10, then one is subtracted to produce +275.1%. This does not guarantee a future return.
When was MaxCyte's analyst forecast verified?
The data was verified on 2026-10-02. The dataset is valid through 2026-10-09.